(Q37942476)

25 August 2017

1 reference

title

Corticosteroid-use in primary and secondary brain tumour patients: a review (English)

1 reference

25 August 2017

Richella Ryan

1

0 references

Sara Booth

object named as

Sara Booth

series ordinal

2

0 references

Stephen J. Price

object named as

Stephen Price

series ordinal

3

0 references

publication date

5 October 2011

1 reference

Journal of Neuro-Oncology

25 August 2017

1 reference

25 August 2017

106

1 reference

25 August 2017

3

1 reference

25 August 2017

449-459

1 reference

https://scigraph.springernature.com/pub.10.1007/s11060-011-0713-3

25 August 2017

0 references

cites work

Genesis of the use of corticosteroids in the treatment and prevention of brain edema

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0713-3

Cortisone and ACTH as an adjunct to the surgery of craniopharyngiomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0713-3

Response criteria for phase II studies of supratentorial malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0713-3

Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0713-3

Defining the impact and contribution of steroids in patients receiving whole-brain irradiation for cerebral metastases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0713-3

The management of brain edema in brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0713-3

Brain endothelial cell-cell junctions: how to "open" the blood brain barrier

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0713-3

Tight junctions of the blood-brain barrier: development, composition and regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0713-3

Occludin expression in microvessels of neoplastic and non-neoplastic human brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0713-3

Claudin-1 and claudin-5 expression and tight junction morphology are altered in blood vessels of human glioblastoma multiforme.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0713-3

Aquaporin-4 expression is increased in oedematous human brain tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0713-3

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0713-3

Vascular endothelial growth factor expression, vascular volume, and, capillary permeability in human brain tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0713-3

Increased leukotriene C4 and vasogenic edema surrounding brain tumors in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0713-3

The eicosanoid cascade: possible role in gliomas and meningiomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0713-3

Mechanism of dexamethasone suppression of brain tumor-associated vascular permeability in rats. Involvement of the glucocorticoid receptor and vascular permeability factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0713-3

Capillary permeability factor secreted by malignant brain tumor. Role in peritumoral brain edema and possible mechanism for anti-edema effect of glucocorticoids

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0713-3

Vascular permeability induced by protein product of malignant brain tumors: inhibition by dexamethasone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0713-3

Dexamethasone coordinately regulates angiopoietin-1 and VEGF: a mechanism of glucocorticoid-induced stabilization of blood-brain barrier

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0713-3

Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0713-3

Dexamethasone-induced abolition of the inflammatory response in an experimental glioma model: a flow cytometry study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0713-3

Dexamethasone treatment of brain tumor patients: effects on regional cerebral blood flow, blood volume, and oxygen utilization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0713-3

Regional cerebral blood flow in peritumoral brain edema during dexamethasone treatment: a xenon-enhanced computed tomographic study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0713-3

The use and toxicity of steroids in the management of patients with brain metastases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0713-3

A prospective survey of the use of dexamethasone on a palliative care unit.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0713-3

Persistent outpatient hyperglycemia is independently associated with decreased survival after primary resection of malignant brain astrocytomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0713-3

Corticosteroid-Induced osteoporosis: detection and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0713-3

Dose-effect relationship of dexamethasone on Karnofsky performance in metastatic brain tumors: a randomized study of doses of 4, 8, and 16 mg per day.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0713-3

Systemic corticosteroid therapy--side effects and their management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0713-3

The cumulative burden of oral corticosteroid side effects and the economic implications of steroid use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0713-3

Interperson variability but intraperson stability of baseline plasma cortisol concentrations, and its relation to feedback sensitivity of the hypothalamo-pituitary-adrenal axis to a low dose of dexamethasone in elderly individuals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0713-3

A polymorphism in the glucocorticoid receptor gene may be associated with and increased sensitivity to glucocorticoids in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0713-3

Polymorphisms in the glucocorticoid receptor gene and their associations with metabolic parameters and body composition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0713-3

Identification of the BclI polymorphism in the glucocorticoid receptor gene: association with sensitivity to glucocorticoids in vivo and body mass index

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0713-3

Benefit of dexamethasone compared with prednisolone for childhood acute lymphoblastic leukaemia: results of the UK Medical Research Council ALL97 randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0713-3

Corticosteroids in terminal cancer--a prospective analysis of current practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0713-3

Strategies for minimizing corticosteroid toxicity: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0713-3

Glucocorticoid-induced myopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0713-3

Steroid requirements during radiotherapy for malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0713-3

Dexamethasone treatment in patients with brain metastases and primary brain tumors: do the benefits outweigh the side-effects?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0713-3

Twice-daily tapering dexamethasone treatment during cranial radiation for newly diagnosed brain metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0713-3

The role of steroids in the management of brain metastases: a systematic review and evidence-based clinical practice guideline

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0713-3

A retrospective observation of corticosteroid use at the end of life in a hospice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0713-3

FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0713-3

Steroid myopathy in cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0713-3

Corticosteroid toxicity in neuro-oncology patients

21 January 2018

1 reference

12 December 2020

Corticosteroid-induced osteoporosis: pathogenesis and prevention

1 reference

12 December 2020

Efficacy and adverse effects of different corticosteroid dose regimens in temporal arteritis: a retrospective study

1 reference

12 December 2020

The prescription of steroids in the terminal phase

1 reference

12 December 2020

Neovasculature induced by vascular endothelial growth factor is fenestrated.

1 reference

12 December 2020

Quantitation of peritumoural oedema and the effect of steroids using NMR-relaxation time imaging and blood-brain barrier analysis

1 reference

12 December 2020

Peptic ulcer disease and other complications in patients receiving dexamethasone palliation for brain metastasis

1 reference

12 December 2020

Acute adverse reactions to prednisone in relation to dosage

1 reference

12 December 2020

An overview of the adverse reactions to adrenal corticosteroids

1 reference

12 December 2020

Corticosteroids for acute ischaemic stroke

1 reference

12 December 2020

Withdrawal acute psychosis after corticosteroid discontinuation

1 reference

12 December 2020

Clinical neurosciences in the decade of the brain: hypotheses in neuro-oncology. VEG/PF acts upon the actin cytoskeleton and is inhibited by dexamethasone: relevance to tumor angiogenesis and vasogenic edema.

1 reference

12 December 2020

Complications of corticosteroid therapy

1 reference

12 December 2020

Management of pituitary-adrenal suppression secondary to corticosteroid therapy

1 reference

12 December 2020

Corticosteroid use in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study

1 reference

12 December 2020

Use of dexamethasone in treatment of cerebral edema associated with brain tumors.

1 reference

12 December 2020

Studies on cerebral edema; reaction of the brain to air exposure; pathologic changes.

1 reference

12 December 2020

Role of bevacizumab therapy in the management of glioblastoma.

1 reference

12 December 2020

Use of dexamethasone in the treatment of cerebral edema resulting from brain tumors and brain surgery

1 reference

12 December 2020

10.1007/S11060-011-0713-3

Identifiers

DOI

1 reference

25 August 2017

1 reference

PubMed ID

21971734